BioSpace News Archive

Policy

Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs

Fractyl Health, Inc. announced U.S. Food and Drug Administration approval of a pivotal Investigational Device Exemption to study Revita’s efficacy in maintaining weight loss following the discontinuation of GLP-1 receptor agonist drug therapy, addressing a key unmet need in the treatment of obesity.

April 1, 2024
·
7 min read
Business

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Akari Therapeutics, Plc, a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the full year 2023 as well as recent company highlights.

April 1, 2024
·
9 min read
Business

Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25

Merck, known as MSD outside of the United States and Canada, will hold its first-quarter 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Thursday, April 25.

April 1, 2024
·
3 min read
Business

Lutris Pharma Appoints Life Sciences and Pharmaceutical Entrepreneur Moshe “Mori” Arkin to Its Board of Directors

Lutris Pharma announced the appointment Moshe “Mori” Arkin, a life sciences and pharmaceutical entrepreneur, and Founder and Chairman of Arkin Holdings, to its Board of Directors.

April 1, 2024
·
3 min read
Biotech Beach

Ionis to present at upcoming investor conferences - April 01, 2024

Ionis Pharmaceuticals, Inc. announced that management will participate in fireside chats at the following investor conferences.

April 1, 2024
·
1 min read
Biotech Beach

Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting

Glaukos Corporation announced today that it will present multiple scientific abstracts at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 5-8, 2024 in Boston, MA.

April 1, 2024
·
9 min read
BioCapital

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

VOYDEYA™ (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).

April 1, 2024
·
27 min read
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024

Rakovina Therapeutics Inc will be hosting an informational webinar on Wednesday, April 3, 2024.

April 1, 2024
·
2 min read
Business

Aculys Pharma Announces Appointment of Hidemasa Tanigaki as New CEO

Aculys Pharma, Inc. announces the appointment of Hidemasa Tanigaki as Chief Executive Officer and Representative Director, effective March 29th.

April 1, 2024
·
2 min read
Drug Development

Foresee Pharmaceuticals Receives Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty

Foresee Pharmaceuticals, announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study.

April 1, 2024
·
4 min read